HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Visser, G. W. Articles by Molthoff, C. F. Search for Related Content PubMed PubMed Citation Articles by Visser, G. W. Articles by Molthoff, C. F.

Optimal Quality ¹³¹I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN

Radionuclide Center Vrije Universiteit and Departments of Obstetrics and Gynecology, Otolaryngology, and Nuclear Medicine/PET Center, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

A novel, facile procedure for efficient coupling of high doses of ¹³¹I to monoclonal antibodies (MAbs) was developed with minimal chemical and radiation damage. Methods: To diminish the radiation and chemical burden during labeling, iodination was performed in a large reaction volume and by temporarily coating the MAb with a minimal amount of IODO-GEN. The MAb was coated by injection of IODO-GEN (dissolved in acetonitrile [MeCN]) into the aqueous MAb solution, and the coating was subsequently removed by addition of ascorbic acid. For chemoprotection before, during, and after PD-10 purification of the ¹³¹I-MAbs, ascorbic acid and human serum albumin were used. The effects of autoradiolysis in the starting ¹³¹I solution were countered by treatment with NaOH and ascorbic acid. For this so-called IODO-GEN–coated MAb method, the sensitive chimeric MAb MOv18 (c-MOv18) and the more robust murine MAbs K928 and E48 were used. The high-dose ¹³¹I-labeled MAbs were characterized for radiochemical purity and MAb integrity by thin-layer chromatography, high-performance liquid chromatography, and sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by phosphor imager quantification. The high-dose ¹³¹I-labeled MAbs were also characterized for immunoreactivity. The radiopharmacokinetics and biodistribution of ¹³¹I-c-MOv18 were analyzed in human tumor–bearing nude mice. For comparison, ¹³¹I-c-MOv18 batches were made using the conventional chloramine-T or IODO-GEN–coated vial method. Results: Conventional high-dose labeling of 5 mg c-MOv18 with 4.4 GBq ¹³¹I resulted in a labeling yield of 60%, a radiochemical purity of 90%, an immunoreactive fraction of 25% (72% being the maximum in the assay used), and the presence of aggregation and degradation products. Using similar amounts of ¹³¹I and MAb in the IODO-GEN–coated MAb method, 85%–89% overall radiochemical yield, at least 99.7% radiochemical purity, and full preservation of MAb integrity and immunoreactivity were achieved. For this labeling, 5 mg MAb were coated with 35 µg IODO-GEN during 3 min in a reaction volume of 6 mL. Also, biodistribution was optimal, and tumor accumulation was superior to that of coinjected ¹²⁵I-c-MOv18 labeled according to the conventional IODO-GEN–coated vial method. Conclusion: A new, facile, high-dose ¹³¹I-labeling method was developed for production of ¹³¹I-labeled MAbs with optimal quality for use in clinical radioimmunotherapy.

Key Words: ¹³¹I labeling • monoclonal antibody MOv18 • IODO-GEN • radioimmunotherapy • immunoreactivity

This article has been cited by other articles:

				A. Hubalewska-Dydejczyk, T. Stompor, M. Kalembkiewicz, M. Krzanowski, R. Mikolajczak, A. Sowa-Staszczak, B. Tabor-Ciepiela, U. Karczmarczyk, B. Kusnierz-Cabala, and W. Sulowicz IDENTIFICATION OF INFLAMED ATHEROSCLEROTIC PLAQUE USING 123I-LABELED INTERLEUKIN-2 SCINTIGRAPHY IN HIGH-RISK PERITONEAL DIALYSIS PATIENTS: A PILOT STUDY Perit. Dial. Int., September 1, 2009; 29(5): 568 - 574. [Abstract] [Full Text] [PDF]

				D. A. Harris, R. Pellikka, O. Gasser, P. Blaeuenstein, R. Waibel, P. A. Schubiger, S. W. King, and M. H. Parseghian In-Line Radiolabeling: A Novel Continuous-Flow System for Commercial-Scale Protein Labeling J. Nucl. Med., July 1, 2009; 50(7): 1178 - 1186. [Abstract] [Full Text] [PDF]

				B. M. Tijink, T. Laeremans, M. Budde, M. S.-v. Walsum, T. Dreier, H. J. de Haard, C. R. Leemans, and G. A.M.S. van Dongen Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology Mol. Cancer Ther., August 1, 2008; 7(8): 2288 - 2297. [Abstract] [Full Text] [PDF]

				M. Silacci, S. S. Brack, N. Spath, A. Buck, S. Hillinger, S. Arni, W. Weder, L. Zardi, and D. Neri Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo Protein Eng. Des. Sel., October 1, 2006; 19(10): 471 - 478. [Abstract] [Full Text] [PDF]

				B. M. Tijink, D. Neri, C. R. Leemans, M. Budde, L. M. Dinkelborg, M. Stigter-van Walsum, L. Zardi, and G. A.M.S. van Dongen Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-Labeled Antibody L19-SIP for Selective Targeting of Tumor Vasculature J. Nucl. Med., July 1, 2006; 47(7): 1127 - 1135. [Abstract] [Full Text] [PDF]

				L. R. Perk, G. W.M. Visser, M. J.W.D. Vosjan, M. Stigter-van Walsum, B. M. Tijink, C. R. Leemans, and G. A.M.S. van Dongen 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab J. Nucl. Med., November 1, 2005; 46(11): 1898 - 1906. [Abstract] [Full Text] [PDF]

				A. O. Schaffland, F. Buchegger, M. Kosinski, C. Antonescu, C. Paschoud, C. Grannavel, R. Pellikka, and A. B. Delaloye 131I-Rituximab: Relationship Between Immunoreactivity and Specific Activity J. Nucl. Med., October 1, 2004; 45(10): 1784 - 1790. [Abstract] [Full Text] [PDF]

				I. Verel, G. W.M. Visser, R. Boellaard, M. Stigter-van Walsum, G. B. Snow, and G. A.M.S van Dongen 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies J. Nucl. Med., August 1, 2003; 44(8): 1271 - 1281. [Abstract] [Full Text] [PDF]